NICE says yes to first drug reappraised from Cancer Drugs Fund

NICE has today recommended bosutinib for treating people with chronic myeloid leukaemia. This drug had previously only been made available on the Cancer Drugs Fund (CDF).  

Bosutinib is the first drug to go through the reappraisal process, where NICE assesses the cost and clinical effectiveness of drugs currently in the old CDF. The current list price for bosutinib is around £45,000 per patient a year, however a discount for use in the NHS has been offered by the manufacturer.

You can review the final draft guidance by clicking here

Tagged with

Published 7. July 2016 in News UK